ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
03/31/201506:08:023 Cheap Dividend Stocks You Can Buy Right Now
03/30/201519:06:11FDA clears new oral formulation of Novartis' Exjade
03/30/201517:12:16ADR Shares End Higher; Carnival Shares Rise
03/30/201508:42:35Novartis teams up with Aduro Biotech in cancer immunotherapy
03/28/201515:03:023 Top Stocks for Obamacare Lovers
03/28/201513:08:023 Little-Known Biotechs Working On Potential Blockbusters
03/28/201512:03:025 Freakishly Expensive Cancer Drugs
03/25/201509:03:02Is It Time for GlaxoSmithKline plc to Change Management?
03/24/201508:11:01Is This The Biggest Threat to Isis Pharmaceuticals Stock?
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/20/201507:56:19Court rejects Amgen's bid to block Neupogen biosimilar
03/20/201507:52:39How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures...
03/19/201518:46:14Judge Denies Amgen's Request to Block Novartis's Biosimilar of...
03/18/201519:18:18How The Rushed Biosimilar Law Is Yielding Go-Slow Launches
03/18/201507:45:27AstraZeneca combo lung disease drug successful in Phase 3 studies
03/17/201517:24:32ADR Shares End Mixed; BHP Billiton Shares Rise
03/17/201507:35:19New indication for Novartis bone marrow disorder drug cleared...
03/17/201504:45:54Novartis Gets EU Approval for Jakavi Rare Blood Cancer Drug

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad